Funder: Osteosarcoma Institute
Due Dates: September 10, 2026 (Letter of Intent) | March 5, 2027 (Invited full proposal)
Funding Amounts: $25,000–$800,000 over one to three years, depending on program
Summary: Supports clinical trials, correlative science, preclinical/translational research, and bold new ideas to advance osteosarcoma treatment.
Key Information: Immunotherapy LOIs will not be considered for the 2026–2027 cycle; antibody-drug conjugates are not necessarily categorized as immunotherapy.
Description
The Osteosarcoma Institute (OSI) funds research to increase treatment options and survival rates for patients with osteosarcoma. Its annual grants span four programs, supporting clinical testing, studies of treatment response, discovery of biological dependencies, and high-risk ideas across the drug-development pathway. Clinical trial proposals should offer strong preclinical rationales and designs that enable rapid assessment of effectiveness.
For the 2026–2027 cycle, OSI prioritizes minimal residual disease and metastatic progression, DNA damage response, and multi-targeted tyrosine kinase inhibitors. Correlative research should explain treatment failure or identify predictors of response, while preclinical work should advance biological insights toward therapeutic value. High-Risk/High-Impact grants emphasize innovation and sound hypotheses rather than extensive preliminary data.
